Insider · CIK 0001225480
Jonathan D Root
director
Files at NARI (Inari Medical, Inc.), OMDA (Omada Health, Inc.), EWTX (Edgewise Therapeutics, Inc.), CARL (CARLSMED, INC.). First filing Jul 24, 2025, latest Jul 24, 2025.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
1 / 0
$7.0M bought, $0 sold
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
CARL: CARLSMED, INC.
CARLOct 9, 2026 · close 14.42
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 75Notable | CARLSMED, INC. | $7.0M 466,666 shares | +2692% | 0% from low-0% from high |
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Oct 5, 2026 | OMDA Omada Health, Inc. | AGrant or award Common Stock | +694 | $0.00 | $0 | 192,571 | 5 d ago |
| Jul 22, 2025 | CARL CARLSMED, INC. | AGrant or award Common Stock | +17,333 | $0.00 | $0 | 17,333 | Jul 24, 2025 |
| Jul 24, 2025 | CARL CARLSMED, INC. | CConversion Common Stockindirect: See footnotes | +2,948,794 | - | - | 2,948,794 | Jul 24, 2025 |
| Jul 24, 2025 | CARL CARLSMED, INC. | CConversion Common Stockindirect: See footnotes | +825,135 | - | - | 3,773,929 | Jul 24, 2025 |
| Jul 24, 2025 | CARL CARLSMED, INC. | CConversion Common Stockindirect: See footnotes | +531,877 | - | - | 4,305,806 | Jul 24, 2025 |
| Jul 24, 2025 | CARL CARLSMED, INC. | CConversion Common Stockindirect: See footnotes | +149,655 | - | - | 149,655 | Jul 24, 2025 |
| Jul 24, 2025 | CARL CARLSMED, INC. | CConversion Common Stockindirect: See footnotes | +41,876 | - | - | 191,531 | Jul 24, 2025 |
| Jul 24, 2025 | CARL CARLSMED, INC. | CConversion Common Stockindirect: See footnotes | +26,993 | - | - | 218,524 | Jul 24, 2025 |
| Jul 24, 2025 | CARL CARLSMED, INC. | CConversion Common Stockindirect: See footnotes | +1,117,743 | - | - | 1,117,743 | Jul 24, 2025 |
| Jul 24, 2025 | CARL CARLSMED, INC. | POpen-market purchase Common Stock | +466,666 | $15.00 | $7.0M | 483,999 | Jul 24, 2025 |
| Jul 24, 2025 | CARL CARLSMED, INC. | CConversion Series A Preferred Stockderivativeindirect: See footnotes | -2,948,794 | - | - | 0 | Jul 24, 2025 |
| Jul 24, 2025 | CARL CARLSMED, INC. | CConversion Series B Preferred Stockderivativeindirect: See footnotes | -825,135 | - | - | 0 | Jul 24, 2025 |
| Jul 24, 2025 | CARL CARLSMED, INC. | CConversion Series C Preferred Stockderivativeindirect: See footnotes | -531,877 | - | - | 0 | Jul 24, 2025 |
| Jul 24, 2025 | CARL CARLSMED, INC. | CConversion Series A Preferred Stockderivativeindirect: See footnotes | -149,655 | - | - | 0 | Jul 24, 2025 |
| Jul 24, 2025 | CARL CARLSMED, INC. | CConversion Series B Preferred Stockderivativeindirect: See footnotes | -41,876 | - | - | 0 | Jul 24, 2025 |
| Jul 24, 2025 | CARL CARLSMED, INC. | CConversion Series C Preferred Stockderivativeindirect: See footnotes | -26,993 | - | - | 0 | Jul 24, 2025 |
| Jul 24, 2025 | CARL CARLSMED, INC. | CConversion Series C Preferred Stockderivativeindirect: See footnotes | -1,117,743 | - | - | 0 | Jul 24, 2025 |
| Jul 5, 2025 | OMDA Omada Health, Inc. | AGrant or award Common Stock | +237 | $0.00 | $0 | 9,973 | Jul 8, 2025 |
| Jun 16, 2025 | EWTX Edgewise Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +30,000 | $0.00 | $0 | 30,000 | Jun 18, 2025 |
| Jun 5, 2025 | OMDA Omada Health, Inc. | AGrant or award Common Stock | +9,736 | $0.00 | $0 | 9,736 | Jun 9, 2025 |
| Jun 9, 2025 | OMDA Omada Health, Inc. | CConversion Common Stockindirect: See footnotes | +4,539,436 | - | - | 4,571,769 | Jun 9, 2025 |
| Jun 9, 2025 | OMDA Omada Health, Inc. | CConversion Common Stockindirect: See footnotes | +145,223 | - | - | 146,257 | Jun 9, 2025 |
| Jun 9, 2025 | OMDA Omada Health, Inc. | CConversion Series A Preferred Stockderivativeindirect: See footnotes | -1,813,927 | - | - | 0 | Jun 9, 2025 |
| Jun 9, 2025 | OMDA Omada Health, Inc. | CConversion Series B Preferred Stockderivativeindirect: See footnotes | -1,775,025 | - | - | 0 | Jun 9, 2025 |
| Jun 9, 2025 | OMDA Omada Health, Inc. | CConversion Series C Preferred Stockderivativeindirect: See footnotes | -357,402 | - | - | 0 | Jun 9, 2025 |
| Jun 9, 2025 | OMDA Omada Health, Inc. | CConversion Series C-1 Preferred Stockderivativeindirect: See footnotes | -258,931 | - | - | 0 | Jun 9, 2025 |
| Jun 9, 2025 | OMDA Omada Health, Inc. | CConversion Series D Preferred Stockderivativeindirect: See footnotes | -334,151 | - | - | 0 | Jun 9, 2025 |
| Jun 9, 2025 | OMDA Omada Health, Inc. | CConversion Series A Preferred Stockderivativeindirect: See footnotes | -58,030 | - | - | 0 | Jun 9, 2025 |
| Jun 9, 2025 | OMDA Omada Health, Inc. | CConversion Series B Preferred Stockderivativeindirect: See footnotes | -56,786 | - | - | 0 | Jun 9, 2025 |
| Jun 9, 2025 | OMDA Omada Health, Inc. | CConversion Series C Preferred Stockderivativeindirect: See footnotes | -11,434 | - | - | 0 | Jun 9, 2025 |
| Jun 9, 2025 | OMDA Omada Health, Inc. | CConversion Series C-1 Preferred Stockderivativeindirect: See footnotes | -8,283 | - | - | 0 | Jun 9, 2025 |
| Jun 9, 2025 | OMDA Omada Health, Inc. | CConversion Series D Preferred Stockderivativeindirect: See footnotes | -10,690 | - | - | 0 | Jun 9, 2025 |
| Feb 19, 2025 | NARI Inari Medical, Inc. | UTender of shares Common Stock | -541,149 | - | - | 0 | Feb 19, 2025 |
| Feb 19, 2025 | NARI Inari Medical, Inc. | UTender of shares Common Stockindirect: Directly Owned by Spouse | -335 | - | - | 0 | Feb 19, 2025 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.